ReviewBMJ global health2022
Sudan virus disease outbreak in Uganda: urgent research gaps.
Review in BMJ global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Ebola virus and Sudan virus infection in humans: a comparison to inform vaccine research and development.Emerging microbes & infections · 2026Review
- Rapid scaling up of screening for Sudan virus disease in healthcare facilities during the 2022 outbreak in Uganda.IJID regions · 2026Article
- A narrative review of filovirus outbreaks in East Africa: lessons for strengthening regional disease surveillance.Tropical medicine and health · 2026Review
- CD4Nature immunology · 2026Article
- A highly potent nanobody-based bispecific therapeutic provides broad-spectrum protection against ebolavirus.Nature communications · 2026Article
- Investigating the Sudan virus outbreak in Uganda through the deployment of a mobile laboratory.BMC infectious diseases · 2026Article
- Article
- Modeling Case Burden and Duration of Sudan Ebola Virus Disease Outbreak in Uganda, 2022.Emerging infectious diseases · 2025Article
- Community perceptions of yellow fever and its treatment practices in regions with reported outbreaks in Uganda: A qualitative study.PLoS neglected tropical diseases · 2025Article
- Cryo-EM structure of Sudan ebolavirus glycoprotein complexed with its human endosomal receptor NPC1.Communications biology · 2025Article
- Sudan Virus Persistence in Immune-Privileged Organs of Nonhuman Primate Survivors.Emerging infectious diseases · 2025Article
- Preparedness of healthcare workers for the Ebola outbreak in Mubende and Kassanda districts, Uganda.Journal of public health in Africa · 2025Article
- Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection.PLoS pathogens · 2024Article
- Community perspectives of Ebola Viral Disease in high-risk transmission border regions of Tanzania: a qualitative inquiry.BMC public health · 2024Article
- Genome-wide CRISPR/Cas9 screen identifies SLC39A9 and PIK3C3 as crucial entry factors for Ebola virus infection.PLoS pathogens · 2024Article
- Article
- Design of universal Ebola virus vaccine candidates via immunofocusing.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- A Flexible, Quantitative Plasmonic-Fluor Lateral Flow Assay for the Rapid Detection ofACS infectious diseases · 2024Article
- Stigma among ebola disease survivors in Mubende and Kassanda districts, Central Uganda, 2022.PLOS global public health · 2024Article
- Design of universal Ebola virus vaccine candidatesbioRxiv : the preprint server for biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The Sudan ebolavirus (SUDV) outbreak highlights our ongoing vulnerability to re-emerging high-consequence infectious diseases. Although the Minister of health in Uganda has initiated public health measures in collaboration with neighbouring countries and with support of the WHO, cases have continued to spread to several regions including the capital. The ongoing transmission, uncertain case numbers and no licensed vaccine or therapeutics available are a cause for concern. We searched four databases for SUDV research using the search terms "SUDV", "Sudan Virus" and "Ebola Sudan". Our analysis identified only 20 SUDV research studies. Most were implemented in the USA and only one in Uganda. Nine studies were on therapeutics, eight on vaccines, one on diagnostics, one in one health and one in social science. Our data highlight a lack of SUDV research and an urgent need for investment to identify an effective vaccine, and optimal supportive care and therapeutic strategies for all at risk groups as a key research priority. Research investments should be prioritised into vaccines and treatment strategies that will be accessible to high-risk populations in affected regions during the outbreak, to protect populations, improve individual outcomes and facilitate outbreak control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.